EMA Initiates Review of Otarmeni’s Hereditary Hearing Loss Gene Therapy; Eli Lilly Announces Phase 2 Plans for VERVE-102 in Cardiovascular Disease

LucidQuest Ventures USA

Overview

Key developments in the cell and gene therapy sector were reported on May 28, 2026, with Otarmeni’s hereditary hearing loss gene therapy entering EMA review. Eli Lilly detailed its Phase 2 clinical trial plans for VERVE-102, a gene-editing therapy for cardiovascular disease. Separately, A2 Bio disclosed early research data for solid tumor CAR T-cell therapy, and the Lupus Research Alliance (LRA) partnered with Genentech to fund lupus CAR T research. BioCardia also updated open-label data for CardiAMP CMI in chronic myocardial ischemia, signaling continued expansion and promising early approvals in diverse disease areas.

In Depth

Key Findings

The cell and gene therapy landscape witnessed several significant advancements as of May 28, 2026. Notably, Otarmeni’s gene therapy for hereditary hearing loss has entered the European Medicines Agency (EMA) review process, escalating expectations for regulatory approval in the rare disease space. Concurrently, Eli Lilly provided detailed plans for the Phase 2 clinical trial of VERVE-102, its gene-editing therapeutic targeting cardiovascular disease, underscoring the potential of gene-editing approaches in widespread chronic conditions.

Technical and Clinical Details

Otarmeni’s gene therapy aims to offer a curative solution for hearing loss caused by specific genetic mutations, with the EMA review signaling recognition of its innovative potential and clinical utility. VERVE-102, utilizing CRISPR technology, is designed for permanent reduction of cholesterol by editing specific genes implicated in atherosclerotic cardiovascular disease, with Phase 2 trials set to further validate its safety and efficacy. Additionally, A2 Bio presented initial data suggesting tumor suppressive effects from its solid tumor CAR T-cell therapy, while the LRA and Genentech’s funding for lupus CAR T research propels autoimmune applications. BioCardia’s CardiAMP CMI provided updated open-label data indicating improved cardiac function in patients with chronic myocardial ischemia.

Background and Industry Context

Cell and gene therapies represent a paradigm shift in treating diseases that have historically been recalcitrant to conventional pharmaceutical interventions, by directly addressing their root causes. The scope of these therapies is rapidly expanding from rare genetic disorders to common chronic conditions, with global regulatory bodies expediting approval pathways for these transformative treatments. The recent announcements reflect the increasing diversification of gene-editing applications and heightened expectations for their role as therapeutic options, particularly for chronic diseases affecting broad patient populations.

Future Outlook

These developments constitute crucial steps towards wider clinical adoption of cell and gene therapies. The EMA’s review of Otarmeni’s therapy and Lilly’s initiation of VERVE-102 Phase 2 trials underscore that regulatory success and large-scale clinical validation are indispensable for commercialization and expanding patient access. Moving forward, the success of ongoing clinical trials, establishment of robust manufacturing processes, and cost reduction strategies will be pivotal in ensuring the broad accessibility and impact of these innovative therapies.